A Korean survey found that while most oncologists believe biosimilars are just as safe and effective as originator drugs, ...

Jeffrey Casberg, RPh, MS, examines upcoming generic and biosimilar competition in the pharmaceutical industry, predicting ...

As Indian pharmaceutical companies supplied 4 of every 10 prescriptions in the US in 2022, generating $1.3 trillion in health ...

On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from ...

Cordavis, a CVS Healthspire company, released a report detailing the current hurdles faced in developing and commercializing ...

April brought 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of ...

Sarfaraz K. Niazi, PhD, explains FDA's new guidance on promotional labeling as well as challenges and insights into how this ...

The FDA approved a high-concentration, citrate-free version of Boehringer Ingelheim’s Cyltezo (adalimumab-adbm), making it ...

Data from a Cencora study showed some misalignment in payer coverage of granulocyte colony-stimulating factor (G-CSF) ...

Clinicians and a pharmacist discuss how they are managing access and assistance with copay assistance program in their practices.

Dive into biosimilar regulations in the US! Test your knowledge with our quiz on FDA rules, naming tricks, post-market safety, and more. Ready for the challenge?

Number 4: The FDA has granted approval for Shanghai Henlius Biotech’s trastuzumab biosimilar, Hercessi (trastuzumab-strf; HLX02), for the treatment of HER2-positive breast cancer. The approval marks ...